-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Impaired placental perfusion and major fetal cardiac defects.
Fantasia I, Andrade W, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;53:68-72. pdf -
Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
Litwinska M, Syngelaki A, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:365-372. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Proposed clinical management of pregnancies after combined screening for preeclampsia at 35-37 weeks' gestation.
Panaitescu AM, Wright D, Militello A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017:50:383-387. pdf -
Proposed clinical management of pregnancies after combined screening for preeclampsia at 19-24 weeks' gestation.
Litwinska M, Wright D, Efeturk T, Ceccacci I, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:367-372. pdf -
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:466-71. pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:42-50. pdf -
Serum free b-human chorionic gonadotropin in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright D, Papadopoulos S, Silva M, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:51-9. pdf -
Serum alpha-fetoprotein in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Bredaki FE, Sciorio C, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:34-41. pdf -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96.